{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:54:41Z","timestamp":1768294481995,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40291-015-0133-8","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T16:16:12Z","timestamp":1426004172000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay"],"prefix":"10.1007","volume":"19","author":[{"given":"F. Anthony","family":"Greco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J.","family":"Lennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"133_CR1","unstructured":"Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT, Lawerence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 9th ed. Philadelphia: Lippincott, Williams and Wilkins; 2011. p. 2033\u20132051."},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2008.10.009","volume":"36","author":"KA Oien","year":"2009","unstructured":"Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009;36:8\u201337.","journal-title":"Semin Oncol."},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00428-014-1545-2","volume":"464","author":"JD Hainsworth","year":"2014","unstructured":"Hainsworth JD, Greco FA. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch. 2014;464:393\u2013402.","journal-title":"Virchows Arch."},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J Clin Oncol. 2012;31:217\u201323.","journal-title":"J Clin Oncol."},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5858\/2006-130-465-MCOHCU","volume":"130","author":"XJ Ma","year":"2006","unstructured":"Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130:465\u201373.","journal-title":"Arch Pathol Lab Med."},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","volume":"13","author":"MG Erlander","year":"2011","unstructured":"Erlander MG, Ma XJ, Kesty NC, et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 2011;13:493\u2013503.","journal-title":"J Mol Diagn."},{"key":"133_CR7","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-11-2972","volume":"18","author":"SE Kerr","year":"2012","unstructured":"Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18:3592\u2013960.","journal-title":"Clin Cancer Res."},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jmoldx.2012.10.001","volume":"15","author":"LM Weiss","year":"2013","unstructured":"Weiss LM, Chu PG, Schroeder BE, et al. Blinded comparator study of immunohistochemical analysis versus 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn. 2013;15:263\u20139.","journal-title":"J Mol Diagn."},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/modpathol.2013.105","volume":"27","author":"SE Kerr","year":"2014","unstructured":"Kerr SE, Schnabel CA, Sullivan PS, et al. Use of a 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors. Mod Pathol. 2014;27:44\u201354.","journal-title":"Mod Pathol."},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djt099","volume":"105","author":"FA Greco","year":"2013","unstructured":"Greco FA, Lennington WJ, Spigel DR, et al. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst. 2013;105:782\u201390.","journal-title":"J Natl Cancer Inst."},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1989.7.9.1281","volume":"7","author":"SJ Horning","year":"1989","unstructured":"Horning SJ, Carrier EK, Rouse RV, et al. Lymphomas presenting as histologically unclassified neoplasms; characteristics and response to treatment. J Clin Oncol. 1989;7:1281\u20137.","journal-title":"J Clin Oncol."},{"key":"133_CR12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO.1995.13.1.274","volume":"13","author":"RJ Motzer","year":"1995","unstructured":"Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenic studies in the diagnosis of patients with midline carcinomas of unknown primary site. J Clin Oncol. 1995;13:274\u201382.","journal-title":"J Clin Oncol."},{"key":"133_CR13","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1200\/JCO.2005.05.0575","volume":"24","author":"JD Hainsworth","year":"2006","unstructured":"Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2006;24:3548\u201356.","journal-title":"J Clin Oncol."}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-015-0133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-015-0133-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-015-0133-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T21:01:02Z","timestamp":1651438862000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-015-0133-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,11]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s40291-015-0133-8","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,11]]}}}